Najat C. Daw, MD

Peer-Reviewed Articles

1. Yu K, Slack Tidwell R, Bathala T, Sheth R, Karki M, Chen J, Qian J, Duan F, Perelli L, Soeung M, Rao P, Siefker-Radtke A, Daw NC, Ingram D, Shamsutdinova D, Wani K, Wang W-L, Lazar A, Zhao Z, Prabhakaran S, Bota-Rabassedas N, Futreal PA, Rare Initiative, Patient Team, Yang L, Lin C, Genovese G, Wang L, Tannir N, Msaouel P. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient renal medullary carcinoma. Clin Cancer Res. e-Pub 2026.
2. Soeung M, Yan X, Zanca C, Qian J, Karki M, Duan F, Khan H, Zhang L, Peng DH, Williams M, He R, Chen Z, Perelli L, Chen J, Tidwell RS, Chauhan PK, Le CN, Lam TNA, Bhattacharya N, Shah R, Ho IL, Gay JP, Carrillo CC, Feng N, Le K, Gao G, Perry TL, Mseeh F, Jiang Y, Xu QA, Zacharias NM, Sheth RA, Bathala TK, Rao P, Daw NC, Tripathi DN, Walker CL, Mohammad MM, Zhang J, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav A, Lang W, Arrechedera CA, Clemente LC, Parra ER, Lu H, Haymaker CL, Wistuba II, Futreal A, Viale A, Soth MJ, Jones P, Marszalek JR, Heffernan T, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: Results of a phase II trial and preclinical evidence. Nat Commun 16(1):10474, 2025. e-Pub 2025. PMID: 41290625.
3. Alqahtani, S, Bitar, SD, Mireles, ME, Corrales-Medina, FF, Herzog, CE, Slopis, JM, Daw NC. Ifosfamide-Induced encephalopathy in children and young adults. Cancers 17(13), 2025. e-Pub 2025. PMID: 40647490.
4. Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Clinical characteristics, management, and outcomes of patients with tenal medullary carcinoma: A single-center retrospective analysis of 135 patients. Eur Urol Oncol 8(2):315-323, 2025. e-Pub 2025. PMID: 39013742.
5. Geller JI, Renfro LA, Grundy PE, Perlman EJ, Kalapurakal JA, Ehrlich PF, Biegel J, Huff V, Warwick AB, Paulino A, Mullen EA, Daw NC, Hoffer FA, Tochner Z, Gow K, Gratias E, Ward DA, Anderson JR, Fernandez CV, Dome JS. Rhabdoid tumor of the kidney and soft tissues: Results from national Wilms tumor study-5 and Children's Oncology Group study AREN0321. Pediatr Blood Cancer 72(3):e31490, 2025. e-Pub 2025. PMID: 39702900.
6. Daw NC, Armstrong AE, Renfro LA, Geller JI, Kalapurakal JA, Khanna G, Paulino AC, Perlman EJ, Ehrlich PF, Gow KW, Warwick AB, Grundy PE, Fernandez CV, Mullen EA, Dome JS. Treatment of focal anaplastic Wilms tumor. Cancer 131(2):e35713, 2025. e-Pub 2025. PMID: 39803937.
7. Schneller N, Daw NC, Throckmorton WR, Mullen EA, DeSmith K, Marcarenhas L, O'Connell C, Fernandez CV, Sutton KS, Venkatramani R. Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting. Pediatr Blood Cancer 72(1), 2025. e-Pub 2025. PMID: 39394977.
8. Meyers PA, Federman N, Daw NC, Anderson PM, Davis LE, Kim A, Macy ME, Pietrofeso A, Ratan R, Riedel RF, Trucco M, Breitmeyer JB, Toretsky JA, Ludwig JA. Open-label, multicenter, phase I/II, first-in-human trial of TK216: A first-generation EWS::FLI1 fusion protein antagonist in Ewing sarcoma. J Clin Oncol 42(31):JCO2400020, 2024. e-Pub 2024. PMID: 38954782.
9. Becktell K, Chen Y, Yasui Y, Phelan R, Armstrong GT, Link M, Oeffinger K, Snyder C, Daw NC, Weil B, Weldon C, Chow EJ, Schwartz CL. Long-term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS). Pediatr Blood Cancer 71(10):e31189, 2024. e-Pub 2024. PMID: 39010279.
10. Truong DD, Weistuch C, Murgas KA, Admane P, King BL, Chauviere Lee J, Lamhamedi-Cherradi SE, Swaminathan J, Daw NC, Gordon N, Gopalakrishnan V, Gorlick RG, Somaiah N, Deasy JO, Mikos AG, Tannenbaum A, Ludwig J. Mapping the single-cell differentiation landscape of osteosarcoma. Clin Cancer Res 30(15):3259-3272, 2024. e-Pub 2024. PMID: 38775859.
11. Benedetti DJ, Renfro LA, Tfirn I, Daw NC, Kalapurakal JA, Ehrlich PF, Khanna G, Perlman E, Warwick A, Gow KW, Paulino AC, Seibel NL, Grundy P, Fernandez CV, Geller JI, Mullen EA, Dome JS. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. Cancer 130(13):2361-2371, 2024. e-Pub 2024. PMID: 38396300.
12. Bronk JK, McAleer MF, McGovern SL, Lassen-Ramshad Y, Safwat A, Daw NC, Rainusso N, Mahajan A, Grosshans DR, Paulino AC. Comprehensive radiotherapy for pediatric Ewing sarcoma: Outcomes of a prospective proton study. Radiother Oncol 195:110270, 2024. e-Pub 2024. PMID: 38583721.
13. Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, Subbiah V. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open 8(6):101609, 2023. e-Pub 2023. PMID: 37879233.
14. Jeyabal P, Bhagat A, Wang F, Roth M, Livingston JA, Gilchrist SC, Banchs J, Hildebrandt MAT, Chandra J, Deswal A, Koutroumpakis E, Wang J, Daw NC, Honey TA, Kleinerman ES. Circulating microRNAs and cytokines as prognostic biomarkers for doxorubicin-induced cardiac injury and for evaluating the effectiveness of an exercise intervention. Clin Cancer Res 29(21):4430-4440, 2023. e-Pub 2023. PMID: 37651264.
15. Daw NC, Saloustros E. Cancer in adolescents and young adults-ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology edition 2023. ESMO Open, JCO Glob Oncol, 2023. e-Pub 2023.
16. Beird HC, Wu CC, Nakazawa M, Ingram D, Daniele JR, Lazcano R, Little L, Davies C, Daw NC, Wani K, Wang WL, Song X, Gumbs C, Zhang J, Rubin B, Conley A, Flanagan AM, Lazar AJ, Futreal PA. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. HGG Adv 4(4):100224, 2023. e-Pub 2023. PMID: 37593416.
17. Oosterom N, Gooskens SLM, Renfro LA, Perlman EJ, van den Heuvel-Eibrink MM, Hamilton TE, Green DM, Grundy PE, Daw NC, Geller JI, Dome JS, Fernandez CV, Mullen EA. Severe hepatopathy in national Wilms tumor studies 3-5: Prevalence, clinical features, and outcomes after reintroduction of chemotherapy. J Clin Oncol 41(26):4247-4256, 2023. e-Pub 2023. PMID: 37343199.
18. Zaky W, Ragoonanan D, Batth I, Dao L, Wang J, Xia X, Daw NC, Gill JB, Khatua S, Li S. Automated capture and analysis of circulating tumor cells in pediatric, adolescent and young adult patients with central nervous system tumors. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568669.
19. Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah I, Zaky W, Gouda MA, Morani AC, Behrang A, Harrison D, Piha-Paul S, Meric-Bernstam F, Gorlick R, Schwartz C, Subbiah V. Everolimus in combination with vandetanib in children, adolescents and young adults: A phase 1 study. ESMO, 2023. e-Pub 2023.
20. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar A, Wang WL, Daw NC, Gill JB, Harrison D, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Contributed equally SV. Impact of biomarker-matched therapies on outcomes in patients with sarcoma enrolled in early-phase clinical trials (SAMBA 101). Clin Cancer Res 29(9):OF1-OF11, 2023. e-Pub 2023. PMID: 37058010.
21. Truong DD, Lamhamedi-Cherradi SE, Porter RW, Krishnan S, Swaminathan J, Gibson A, Lazar AJ, Livingston JA, Gopalakrishnan V, Gordon N, Daw NC, Navin NE, Gorlick R, Ludwig JA. Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing. BMC Cancer 23(1):488, 2023. e-Pub 2023. PMID: 37254069.
22. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
23. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: A single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
24. van der Perk MEM, Cost NG, Bos A ME, Brannigan R, Chowdhury T, Davidoff AM, Daw NC, Dome JS, Ehrlich P, Graf N, Geller J, Kalapurakal J, Kieran K, Malek M, McAleer MF, Mullen E, Pater L, Polanco A, Romao R, Saltzman AF, Walz AL, Woods AD, van den Heuvel-Eibrink MM, Fernandez CV. White paper: Onco-fertility in pediatric patients with Wilms tumor. Int J Cancer 151(6):843-858, 2022. e-Pub 2022. PMID: 35342935.
25. Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JA. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun 13(1):3057, 2022. e-Pub 2022. PMID: 35650195.
26. Molina ER, Chim LK, S-E L, Mohiuddin S, McCall D, Cuglievan B, Krishnan S, Porter RW, Ingram DR, W-L W, Lazar AJ, Scott DS, Truong D, Daw NC, Ludwig JA, Mikos AG. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget 13(1):521-533, 2022. e-Pub 2022. PMID: 35284040.
27. Piha-Paul SA, Dumbrava E, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp D, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner P. A phase I trial of the MET/ALK/ROS1 Inhibitor Crizotinib combined with the VEGF Inhibitor Pazopanib in patients with advanced solid malignancies. Onco Targets Ther 14:3037–3049, 2021. e-Pub 2021. PMID: 33994796.
28. Ragoonanan DS, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar JH, Dailey-Garnes N, Petropoulos D, Tewari P, Bhatti MM, Ahmad A, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill J, Zaky W, Daw NC, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall E, Champlin R, Mahadeo KM. Cancer immunotherapy, severe immune-related adverse events, multi-inflammatory syndrome and severe acute respiratory syndrome Coronavirus 2. Front Oncol 11, 2021. e-Pub 2021. PMID: 33614514.
29. S-E L, Mohiuddin S, Mishra DK, Krishnan S, Ruiz Velasco A, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, and Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther 28(12):1325-1338, 2021. e-Pub 2021. PMID: 33408328.
30. Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill J, Liu F, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman ES, Gorlick R, Daw NC, Li S. Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Front Oncol 11:760267, 2021. e-Pub 2021. PMID: 34956881.
31. Rathore R, Caldwell KE, Schutt C, Brashears CB, Prudner BC, Wang W, Leung CH, Lin H, Daw NC, Giles A, Lazar A, Chrisinger J, Livingston JA, Van Tine BA. Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. Cell Reports 34(108678), 2020. e-Pub 2020. PMID: 33503424.
32. Geller JI, Cost NG, Chi YY, Tornwall B, Cajaiba M, Perlman EJ, Kim Y, Mullen EA, Glick RD, Khanna G, Daw NC, Ehrlich P, Fernandez CV, Dome JS, Tumor Committee COGR. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. Cancer 126(23):5156-5164, 2020. e-Pub 2020. PMID: 32926409.
33. Tarek N, Said R, Andersen CA, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing sarcoma/ primitive neuroectodermal tumor of the kidney: The MD Anderson Cancer Center experience. Cancers, 2020. e-Pub 2020. PMID: 33050651.
34. Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Co-first authors LJ. IGF-1R/mTOR targeted therapy for Ewing sarcoma: A meta-analysis of five IGF-1R-related trials matched to proteomic and radiologic predictive biomarkers. Cancers 12(7), 2020. e-Pub 2020. PMID: 32630797.
35. Daw NC, Chi YY, Kalapurakal JA, Kim Y, Hoffer FA, Geller JI, Perlman EJ, Ehrlich PF, Mullen EA, Warwick AB, Grundy PE, Paulino AC, Gratias E, Ward D, Anderson JR, Khanna G, Tornwall B, Fernandez CV, Dome JS, Committee AS. Activity of vincristine and irinotecan in diffuse anaplastic Wilms tumor and therapy outcomes of stage II to IV disease: Results of the Children's Oncology Group AREN0321 study. J Clin Oncol 38(14):JCO1901265, 2020. e-Pub 2020. PMID: 32134700.
36. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
37. Daw NC, Chi YY, Kim Y, Mullen EA, Kalapurakal JA, Tian J, Khanna G, Geller JI, Perlman EJ, Ehrlich PF, Warwick AB, Grundy PE, Fernandez CV, Dome JS, Committee AS. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. Eur J Cancer 118:58-66, 2019. e-Pub 2019. PMID: 31325873.
38. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: A phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
39. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer 17(1):1-6, 2019. e-Pub 2019. PMID: 30287223.
40. Im HJ, Solaiyappan M, Lee I, Bradshaw T, Daw NC, Navid F, Shulkin BL, Cho SY. Multi-level otsu method to define metabolic tumor volume in positron emission tomography. Am J Nucl Med Mol Imaging 8(6):373-386, 2018. e-Pub 2018. PMID: 30697457.
41. Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality treatment of desmoplastic small round cell tumor: Chemotherapy and complete cytoreductive surgery improve patient survival. Clin Cancer Res 24(19):4865-4873, 2018. e-Pub 2018. PMID: 29871905.
42. Bishop MW, Advani SM, Villarroel M, Billups CA, Navid F, Rivera C, Quintana JA, Gattuso JS, Hinds PS, Daw NC. Health-related quality of life and survival outcomes of pediatric patients with non-metastatic osteosarcoma treated in countries of different resources. J Glob Oncol 4:1-11, 2018. e-Pub 2018. PMID: 30241221.
43. Yedururi S, Chawla S, Amini B, Wei W, Salem UI, Morani AC, Wang WL, Gorlick R, Lewis VO, Daw NC. Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. Eur J Radiol 105:49-55, 2018. e-Pub 2018. PMID: 30017298.
44. Livingston JA, Wang WL, Tsai JW, Lazar AJ, Leung CH, Lin H, Advani S, Daw NC, Santiago-O'Farrill J, Hollomon M, Gordon NB, Kleinerman ES. Analysis of HSP27 and the autophagy marker LC3B+ puncta following preoperative chemotherapy identifies high-risk osteosarcoma patients. Mol Cancer Ther 17(6):1315-1323, 2018. e-Pub 2018. PMID: 29592877.
45. Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer 17(2):287-294, 2018. e-Pub 2018. PMID: 28988289.
46. Im HJ, Zhang Y, Wu H, Wu J, Daw NC, Navid F, Shulkin BL, Cho SY. Prognostic value of metabolic and volumetric parameters of FDG PET in pediatric osteosarcoma: A hypothesis-generating study. Radiology 287(1):303-312, 2018. e-Pub 2018. PMID: 29357275.
47. Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw NC, Hayes-Jordan A, Ludwig JA. Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor. Oncologist 23(3):360-366, 2018. e-Pub 2018. PMID: 29212731.
48. Davis JC, Daw NC, Navid F, Billups CA, Wu J, Bahrami A, Jenkins JJ, Snyder SE, Reddick WE, Santana VM, McCarville MB, Guo J, Shulkin BL. FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. J Nucl Med 59(1):25-30, 2018. e-Pub 2018. PMID: 28611244.
49. Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int J Cancer 141(7):1469-1477, 2017. e-Pub 2017. PMID: 28631382.
50. Huh WW, Daw NC, Herzog CE, Munsell MF, McAleer MF, Lewis VO. Ewing sarcoma family of tumors in children younger than 10 years of age. Pediatr Blood Cancer 64(4), 2017. e-Pub 2017. PMID: 27696711.
51. Anghelescu DL, Steen BD, Wu H, Wu J, Daw NC, Rao BN, Neel MD, Navid F. Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. Pediatr Blood Cancer 64(3), 2017. e-Pub 2017. PMID: 27573717.
52. Salem U, Amini B, Chuang HH, Daw NC, Wei W, Haygood TM, Madewell JE, Costelloe CM. 18F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone. J Cancer 8(15):2892-2898, 2017. e-Pub 2017. PMID: 28928879.
53. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR blockade: Novel resistance mechanisms and synergistic drug combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
54. Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer 63(10):1761-70, 2016. e-Pub 2016. PMID: 27362300.
55. Daw NC, Laack NN, McIlvaine EJ, Krailo M, Womer RB, Granowetter L, Grier HE, Marina NM, Bernstein ML, Gebhardt MC, Marcus KJ, Advani SM, Healey JH, Letson GD, Gorlick RG, Randall RL. Local control modality and outcome in Ewing sarcoma of the femur: A report from the Children's Oncology Group. Ann Surg Oncol 23(11):3541-47, 2016. e-Pub 2016. PMID: 27216741.
56. Hurley C, McCarville MB, Shulkin BL, Mao S, Wu J, Navid F, Daw NC, Pappo AS, Bishop MW. Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. Pediatr Blood Cancer 63(8):1381-6, 2016. e-Pub 2016. PMID: 27082077.
57. Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Casanova M, Merks JH, Massimino M, Grill J, Daw NC, Navid F, Jin J, Allison DE. Bevacizumab dosing strategy in pediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 81(1):148-160, 2016. e-Pub 2016. PMID: 26345283.
58. Yedururi S, Morani AC, Gladish GW, Vallabhaneni S, Anderson PM, Hughes D, Wang WL, Daw NC. Cardiovascular involvement by osteosarcoma: An analysis of 20 patients. Pediatr Radiol 46(1):21-33, 2016. e-Pub 2016. PMID: 26411434.
59. Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer 113(9):1282-1288, 2015. e-Pub 2015. PMID: 26461056.
60. Loh AH, Wu H, Bahrami A, Navid F, McCarville MB, Wang C, Wu J, Bishop MW, Daw NC, Neel MD, Rao BN. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma. Pediatr Blood Cancer 62(2):246-251, 2015. e-Pub 2015. PMID: 25381958.
61. Daw NC, Chou AJ, Jaffe N, Rao BN, Billups CA, Rodriguez-Galindo C, Meyers PA, Huh WW. Recurrent osteosarcoma with a single pulmonary metastasis: A multi-institutional review. Br J Cancer 112(2):278-82, 2015. e-Pub 2015. PMID: 25422914.
62. Pan HY, Morani A, Wang WL, Hess KR, Paulino AC, Ludwig JA, Lin PP, Daw NC, Mahajan A. Prognostic factors and patterns of relapse in Ewing sarcoma patients treated with chemotherapy and R0 resection. Int J Radiat Oncol Biol Phys 92(2):349-57, 2015. e-Pub 2015. PMID: 25772182.
63. Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: Implications for dosing. Clin Cancer Res 20(10):2783-92, 2014. e-Pub 2014. PMID: 24637635.
64. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatte P, Wu J, Mao S, Boggs K, Mulder H, Yergeau D, Lu C, Ding L, Edmonson M, Qu C, Wang J, Li Y, Navid F, Daw NC, Mardis ER, Wilson RK, Downing JR, Zhang J, Genome Project DMSJCRHUPC. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 7(1):104-12, 2014. e-Pub 2014. PMID: 24703847.
65. Ness KK, Neel MD, Kaste SC, Billups CA, Marchese VG, Rao BN, Daw NC. A comparison of function after limb salvage with non-invasive expandable or modular prostheses in children. Eur J Cancer 50(18):3212-20, 2014. e-Pub 2014. PMID: 25459397.
66. McCarville MB, Billups C, Wu J, Kaufman R, Kaste S, Coleman J, Sharp S, Nadel H, Charron M, Lederman H, Don S, Shochat S, Daw NC, Shulkin B. The role of PET-CT in assessing pulmonary nodules in children with solid malignancies. Am J Roentgenol 201(6):W900-W905, 2013. e-Pub 2013.
67. Kaste SC, Brady SL, Yee B, McPherson VJ, Kaufman RA, Billups CA, Daw NC, Pappo AS. Is routine pelvic surveillance imaging necessary in patients with Wilms’ tumor?. Cancer 119(1):182-8, 2013. e-Pub 2013. PMID: 22736193.
68. Daw NC, Mahajan A. Photons or protons for non-central nervous system solid malignancies in children: a historical perspective and important highlights. Am Soc Clin Oncol Educ Book:354-9, 2013. e-Pub 2013. PMID: 23714546.
69. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. Cancer 119(14):2645-53, 2013. e-Pub 2013. PMID: 23625626.
70. Krasin MJ, Wiese KM, Spunt SL, Hua CH, Daw NC, Navid F, Davidoff AM, McGregor L, Merchant TE, Kun LE, McCrarey L, Hoth KA, Yan X, Xiong X. Jaw dysfunction related to pterygoid and masseter muscle dosimetry after radiation therapy in children and young adults with head-and-neck sarcomas. Int J Radiat Oncol Biol Phys 82(1):355-60, 2012. e-Pub 2012. PMID: 21093167.
71. Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, Hoffer FA, Kaste SC, Jenkins JJ, Ortega Flores XC, Quintana J, Villarroel M, Daw NC. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival for pediatric patients with osteosarcoma. Cancer 118(15):3776-85, 2012. e-Pub 2012. PMID: 22180392.
72. Fernandez-Pineda I, Daw NC, McCarville MB, Emanus LJ, Rao BN, Davidoff AM, Shochat SJ. Osteosarcoma patients with a single pulmonary nodule on CT: A single institution experience. J Pediatr Surg 47(6):1250-4, 2012. e-Pub 2012. PMID: 22703801.
73. Carr S, Allison KJ, Velde L-A VD, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 204(10):1475-82. e-Pub 2011. PMID: 21949042.
74. Debelenko LV, Raimondi SC, Daw NC, Shivakumar BR, Huang D, Nelson M, Bridge JA. Renal cell carcinoma with novel VCL-ALK fusion: New representative of ALK-associated tumor spectrum. Mod Pathol 24(3):430-42, 2011. e-Pub 2011. PMID: 21076462.
75. Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patiño-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schüz J, Craft AW, Savage SA. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control 22(6):899-908, 2011. e-Pub 2011. PMID: 21465145.
76. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial. Cancer 117(12):2770-8, 2011. e-Pub 2011. PMID: 21656756.
77. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan JS, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Preliminary efficacy of the anti-insulin like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing Sarcoma. Journal of Clinical Oncology 29(34):4534-40, 2011. e-Pub 2011. PMID: 22025154.
78. Moinul Hossain AK, Shulkin BL, Gelfand MJ, Bashir H, Daw NC, Sharp SE, Nadel HR, Dome JS. FDG positron emission tomography/computed tomography studies of Wilms' tumor. Eur J Nucl Med Mol Imaging 37(7):1300-1308, 2010. e-Pub 2010. PMID: 20204356.
79. Kaste SC, Waszilycsak GL, McCarville MB, Daw NC. Estimation of potential excess cancer incidence in pediatric 201Tl imaging. Am J Roentgenol 194(1):245-9, 2010. e-Pub 2010. PMID: 20028929.
80. McKibbin T, Zhao W, Tagen M, Daw NC, Furman WL, McGregor LM, Geyer JR, Allen JW, Stewart CF. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. Eur J Cancer 46(11):2045-2051, 2010. e-Pub 2010. PMID: 20621735.
81. Hoffer FA, Daw NC, Xiong X, Anghelescu D, Krasin M, Yan X, Davidoff AM, Furman WL, Rodriguez-Galindo C, Spunt SL. A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer 115(6):1328-1337, 2009. e-Pub 2009. PMID: 19180637.
82. Daw NC, Gregornik D, Rodman J, Marina N, Wu J, Kun LE, Jenkins JJ, McPherson V, Wilimas J, Jones DP. Renal function after ifosfamide, carboplatin, and etoposide (ICE) chemotherapy, nephrectomy, and radiotherapy in children with Wilms tumor. European Journal of Cancer 45(1):99-106, 2009. e-Pub 2009. PMID: 18996004.
83. Hinds PS, Gattuso JS, Billups CA, West NK, Wu J, Rivera C, Quintana J, Villarroel M, Daw NC. Aggressive treatment of nonmetastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer 45(11):2007-2014, 2009. e-Pub 2009. PMID: 19450974.
84. Hinds PS, Billups CA, Cao X, Gattuso JS, Burghen E, West N, Rubnitz JE, Daw NC. Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia. Eur J Oncol Nurs 13(3):156-163, 2009. e-Pub 2009.
85. Klosky JL, Randolph-Frye ME, Navid F, Gamble HL, Spunt SL, Metzger ML, Daw NC, Morris EB, Hudson MM. Sperm cryopreservation practices among adolescent cancer patients at risk for infertility. Pediatric Hematology/Oncology 26(4):252-260, 2009. e-Pub 2009. PMID: 19437327.
86. Furman WL, Navid F, Daw NC, McCarville MB, Lm M, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 27(27):4599-4604, 2009. e-Pub 2009. PMID: 19687340.
87. Ness KK, Rao BN, Daw NC. More than physical function: HRQOL among children and adolescents with lower extremity bone sarcoma. Pediatr Blood Cancer 53(3):310-311, 2009. e-Pub 2009. PMID: 19544376.
88. Wright KD, Green DM, Daw NC. Late effects of treatment for Wilms tumor. Pediatric Hematology/Oncology 26(6):407-413, 2009. e-Pub 2009. PMID: 19657990.
89. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F. Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer 50(6):1147-1153, 2008. e-Pub 2008.
90. Inaba H, Khan RB, Laningham FH, Crews KR, C-H P, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 19(1):178-184, 2008. e-Pub 2008.
91. Rivera GK, Quintana J Villarroel M, Santana VM, Rodriguez-Galindo C, Neel MD, Velez G, Ribeiro RC, Daw NC. Transfer of complex frontline anticancer therapy to a developing country: The St. Jude osteosarcoma experience in Chile. Pediatr Blood Cancer 50:1143-1146, 2008. e-Pub 2008.
92. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC, Khoury JD. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113(6):1453-1461, 2008. e-Pub 2008.
93. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in treatment of children and young adults with refractory bone sarcoma. Cancer 113(2):419-425, 2008. e-Pub 2008.
94. Rodriguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM, Navid F. Analysis of prognostic factors in Ewing's sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies. Cancer 110(2):375-384, 2007. e-Pub 2007.
95. Metzger ML, Stewart CF, Freeman III BB, Billups CA, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen EA, Alvarado C, Daw NC, Dome JS. Topotecan is active against Wilms' tumor: Results of a multi-institutional Phase II study. Journal of Clinical Oncology 25(21):3130-3136, 2007. e-Pub 2007.
96. Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer 49(3):352-357, 2007. e-Pub 2007.
97. Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. British Journal of Cancer 97(11):1552-1559, 2007. e-Pub 2007.
98. Weiss A, Khoury JD, Hoffer FA, Wu J, Billups CA, Heck RK, Quintant J, Poe D, Rao BN, Daw NC. Telangiectatic osteosarcoma: The St. Jude Children's Research Hospital's experience. Cancer 109(8):1627-1637, 2007. e-Pub 2007.
99. McCarville MB, Barton EH, Cameron JR, Xiong X, Daw NC, Kaste SC, Wu S, Glass JO, Reddick WE. The cause and clinical significance of central tumor photopenia on thallium scintigraphy of pediatric osteosarcoma of the extremity. Am J Roentgenol 188:572-578, 2007. e-Pub 2007.
100. McCarville MB, Lederman H, Santana VM, Daw NC, Shochat SJ, C-S L, Kaufman RA. Distinguishing benign from malignant pulmonary nodules with helical chest CT in children with malignant solid tumors. Radiology 239(2):514-520, 2006. e-Pub 2006.
101. Daw NC, Jenkins JJ, McCarville MB, Rao BN, Neel MN. Polymethylmethacrylate lung embolus after limb-salvage surgery of the distal femur. Clin Orthopaed Rel Res 448:252-256, 2006. e-Pub 2006.
102. Rodriguez-Galindo C, Crews KR, Stewart CF, Furman W, Panetta JC, Daw NC, Cain AM, Tan M, Houghton PJ, Santana VM. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 57(1):15-24, 2006. e-Pub 2006.
103. Freeman III BB, Daw NC, Geyer JR, Furman WL, Stewart CF. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 24(3):310-317, 2006. e-Pub 2006.
104. Turner PK, Iacono LC, Panetta JC, Santana VM, Daw NC, Gajjar A, Stewart CF. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemother Pharmacol 57(4):475-482, 2006. e-Pub 2006.
105. Hartford CM, Wodowski KS, Rao BN, Khoury JD, Neel MD, Daw NC. Osteosarcoma among children aged 5 years or younger: The St. Jude Children's Research Hospital experience. Journal of Pediatric Hematology/Oncology 28:43-47, 2006. e-Pub 2006.
106. Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 24(4)(563-570), 2006. e-Pub 2006.
107. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH. Metastatic osteosarcoma: Results of two consecutive therapeutic trials at St. Jude Children's Research Hospital. Cancer 106:403-412, 2006. e-Pub 2006.
108. Kaste SC, Fuller CE, Saharia A, Rao BN, Daw NC. Pediatric surface osteosarcoma: Clinical, pathologic, and radiologic features. Pediatr Blood Cancer 47(2):152-162, 2006. e-Pub 2006.
109. Saab R, Rao BN, Rodriguez-Galindo C, Billups CA, Fortenberry TN, Daw NC. Osteosarcoma of the pelvis in children and young adults: The St. Jude Children's Research Hospital's experience. Cancer 103(7):1468-1474, 2005. e-Pub 2005.
110. Gaur AH, Liu T, Knapp KM, Daw NC, Rao BN, Neel MD, Rodriguez-Galindo C, Brand D, Adderson EE. Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer 104(3):602-610, 2005. e-Pub 2005.
111. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group Study. Journal of Clinical Oncology 23(25):6172-6180, 2005. e-Pub 2005.
112. Miller ML, Obert CA, Gao G, Daw NC, Flynn P, Tuomanen E. Cephalosporin-resistant pneumococci and sickle cell disease. Emerg Infect Dis 11(8):1192-1196, 2005. e-Pub 2005.
113. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. Am J Roentgenol 184(4):1293-1304, 2005. e-Pub 2005.
114. Hayes-Jordan AA, Daw NC, Furman WL, Hoffer FA, Shochat SJ. Tumor recurrence at thoracostomy-tube insertion sites: A report of 2 pediatric cases. Journal of Pediatric Surgery 39(10):1565-1567, 2004. e-Pub 2004. PMID: 18996004.
115. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw NC, Jenkins III JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Research 64(20):7491-7499, 2004. e-Pub 2004.
116. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma: The St. Jude Children's Research Hospital experience and a review of the literature. Cancer 101:39-50, 2004. e-Pub 2004.
117. Rodriguez-Galindo C, Shah N, McCarville MB, Billups CA, Neel MN, Rao BN, Daw NC. Outcome after local recurrence of osteosarcoma: The St. Jude Children's Research Hospital experience (1970-2000). Cancer 100:1928-1935, 2004. e-Pub 2004.
118. Neel MD, Heck RK, Britton L, Daw NC, Rao BN. Use of a smooth press-fit stem preserves physical growth after tumor resection. Clin Orthopaed Rel Res 426:125-128, 2004. e-Pub 2004.
119. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, and Stewart CF. A phase I and pharmacokinetic study of oral topotecan administered once daily for five days for two consecutive weeks to pediatric patients with refractory solid tumors. Journal of Clinical Oncology 22:829-837, 2004. e-Pub 2004.
120. Crews KR, Stewart CF, Liu T, Rodriguez-Galindo C, Santana VM, Daw NC. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. Journal of Pediatric Hematology/Oncology 26(11):764-767, 2004. e-Pub 2004.
121. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100:1724-1733, 2004. e-Pub 2004.
122. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. Journal of Clinical Oncology 22(18):3790-3797, 2004. e-Pub 2004.
123. Sajadi KR, Heck RK, Neel MD, Rao BN, Daw NC, Rodriguez-Galindo C, Hoffer FA, Stacy GS, Peabody TD, Simon MA. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthopaed Rel Res 426:92-96, 2004. e-Pub 2004.
124. Kaste SC, Liu T, Billups CA, Daw NC, Pratt CB, Meyer WH. Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 43(7):723-728, 2004. e-Pub 2004.
125. McNall RY, Nowicki PD, Miller B, Billups CA, Liu T, Daw NC. Adenocarcinoma of the cervix and vagina in pediatric patients: An analysis of 38 cases. Pediatr Blood Cancer 43(3):289-294, 2004. e-Pub 2004.
126. Daw NC, Billups CA, Pappo AS, Jenkins JJ, Mahmoud HH, Krasin MJ, Rao BN. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients. Cancer 97:2839-2847, 2003. e-Pub 2003.
127. Okamoto Y, Mathew S, Daw NC, Neel MD McCarville MB, Dome JS, and Hill DA. Giant cell tumor of bone with pulmonary metastases. Medical Pediatric Oncology 41(5):454-459, 2003. e-Pub 2003.
128. Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome J, Pappo AS, Rao BN, Pratt CB. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. Journal of Pediatric Hematology/Oncology 24:250-255, 2002. e-Pub 2002.
129. Neel MD, Toy PC, Kaste SC, Jenkins JJ, Daw NC, Rao BN. Painful limp in a 10-year-old boy. Clin Orthopaed Rel Res, Orthopaedic. Radiology. Pathology Conference 410:326-333, 2002. e-Pub 2002.
130. Daw NC, Kauffman WM, Bodner SM, Pratt CB, Hoffer FA. Patterns of abdominal relapse and role of sonography in Wilms tumor. Journal of Pediatric Hematology/Oncology 19:107-115, 2002. e-Pub 2002.
131. Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw NC, Billups CA, Wilimas JA. Improved survival for patients with recurrent Wilms tumor: The experience at St. Jude Children's Research Hospital. Journal of Pediatric Hematology/Oncology 24:192-198, 2002. e-Pub 2002.
132. Daw NC, Kaste SC, Hill DA, Kun LE, Pratt CB. Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report. Pediatric Hematology Oncology 18:123-128, 2001. e-Pub 2001.
133. Abushullaih BA, Pestina TI, Srivastava DK, Jackson CW, Daw NC. A schedule of recombinant Mp1 ligand highly effective at preventing lethal myelosuppression in mice given carboplatin and radiation. Experimental Hematology 29:1425-1431, 2001. e-Pub 2001.
134. Rodriguez-Galindo C, Poquette CA, Daw NC, Tan M, Meyer WM, and Cleveland JL. Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Medical Pediatric Oncology 36:605-611, 2001. e-Pub 2001.
135. Daw NC, Mahmoud HH, Meyer WH, Jenkins JJ Kaste SC, Poquette CA, Kun LE, Pratt CB, Rao BN. Bone sarcomas of the head and neck in children: The St. Jude Children's Research Hospital experience. Cancer 88:2172-2180, 2000. e-Pub 2000.
136. Daw NC, Arnold JT, Abushullaih BA, Stenberg PE, White MW, Jayawardene D, Srivastava DK, Jackson CW. A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. Blood 91(2):466-474, 1998. e-Pub 1998.
137. Daw NC, Wilimas JA, Wang WC, Presbury GJ, Joyner RE, Harris SC, Davis Y, Chen G, Chesney PJ. Nasopharyngeal carriage of Penicillin-resistant streptococcus pneumoniae in children with sickle cell disease. Pediatrics 99(4):e7, 1997. e-Pub 1997.
138. Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine Megakaryocyte Growth and Development Factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size and ploidization. Blood 89(3):823-833, 1997. e-Pub 1997.

Invited Articles

1. Costelloe CM, Chuang HH, Daw NC. PET/CT of osteosarcoma and Ewing sarcoma. Semin Roentgenol 52(4):255-268, 2017. e-Pub 2017. PMID: 28965545.

Review Articles

1. Ortiz M, Wens F, Hong A, Quarello P, Verschuur A, Tracy E, Daw NC, Dome J, Walz A, Sprokkerieft J, Tygat G, Kentsis A, Libes-Bander J, Schoettler P, Perotti D, Drost J, Venkatramani R, Geller J, van den Heuvel-Eibrink M. Relapsed rhabdoid tumors and other non-nephroblastoma childhood and adolescent kidney tumors: Perspectives from the HARMONICA collaboration. Nat Rev Urol. e-Pub 2025.
2. Walz AL, Maschietto M, Crompton B, Evageliou N, Dix D, Tytgat G, Gessler M, Gisselsson D, Daw NC, Wegert J. Tumor biology, biomarkers and liquid biopsy in pediatric renal tumors. Pediatr Blood Cancer 70 Suppl 2(S2):e30130, 2023. e-Pub 2023. PMID: 36592003.
3. Dome JS, Mullen EA, Dix DB, Gratias EJ, Ehrlich PF, Daw NC, Geller JI, Chintagumpala M, Khanna G, Kalapurakal JA, Renfro LA, Perlman EJ, Grundy PE, Fernandez CV. Impact of the first generation of Children's Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw 19(8):978-985, 2021. e-Pub 2021. PMID: 34416705.

Other Articles

1. Ramakrishnan R, Anjier A, Rav E, Zheng Y, Acahrya S, Basar R, Rezvani K, Wang W, Wani K, Ingram D, Daw NC, Gopalakrishnan V, Kleinerman E, Gordon AN Identifying the potential contribution of cytokines in the cytotoxicity of CD70 directed chimeric antigen receptor natural killer (CAR NK) cells against osteosarcoma. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, Houston, TX,.

Abstracts

1. Ortiz MV, Renfro LA, Cost NG, Tracy ET, Ehrlich P, Sandberg J, Khanna G, Daw NC, Hong AL, Paulino A, Gulliver J, Dome JS, Geller JI, Mullen EA. Features and outcomes of patients with Wilms tumor presenting after the first decade of life: A Report from the Children’s Oncology Group Study AREN03B2. 56th Congress of International Society of Paediatric Oncology, Honolulu, HI,, 2024. e-Pub 2024.
2. Ramakrishnan R, Yedururi S, Throckmorton W, Rao P, Daw NC. Promising treatment for metastatic pediatric translocation type renal cell carcinoma with cabozantinib. 56th Congress of International Society of Paediatric Oncology, Honolulu, HI,, 2024. e-Pub 2024.
3. Soeung M, Yan X, Zhang L, Perelli L, Chen J, Tidwell BS, Khan H, Le CN, Lam TN, Bhattacharya N, Shah R, Ho I, Chen Z, Lundgren SR, Feng N, Zanca C, Karki M, Millward NMZ, He R, Sheth RA, Tharakeswara BK, Rao R, Daw NC, Tripathi DN, Walker, CL, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav AS, Lang W, Arrechedera CA, Clemente LC, Parra-Cuentas ER, Lu H, Haymaker C, Wistuba II, Futreal A, Heffernan T, Viale A, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. Hyperprogression due to myeloid mimicry in renal medullary carcinoma treated with nivolumab plus ipilimumab. Cancer Res 84(6_Supplement):2702, 2024. e-Pub 2024.
4. Benedetti DJ, Renfro LA, Tfirn I, Daw NC, Kalapurakal JA, Ehrlich PF, Khanna G, Perlman E, Warwick A, Gow KW, Paulino AC, Seibel NL, Grundy P, Fernandez CV, Geller JI, Mullen EA, Dome JS. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. 55th Congress of the International Society of Paediatric Oncology, Ottawa, Canada, 70(8):S105-S106, 2023. e-Pub 2023.
5. Rav E, Anjier A, Acharya S, Basar R, Zheng Y, Maegawa S, Shrestha P, Yi W, Daw NC, Rezvani K, Gopalakrishnan V, Gorlick R, Kleinerman E, Gordon N. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. CTOS 2023 Annual Meeting,, 2023. e-Pub 2023.
6. Rav E, Anjier A, Acharya S, Basar R, Zheng Y, Maegawa S, Shrestha P, Wang Y, Daw NC, Rezvani K, Gopalakrishnan V, Gorlick R, Kleinerman E, Gordon N. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. Innovations in Cancer Prevention and Research Conference,, 2023. e-Pub 2023.
7. Khazal S, Gill J, Foglesong J, Yedururi S, Morani A, Sui D, Bassett R, Gettys S, Mahadeo K, Gorlick R, Shpall E, Rezvani K, Daw NC. A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood derived natural killer cell immunotherapy for pediatric solid tumor malignancies. ASCO 2023 Annual Meeting, Chicago, IL,, 2023. e-Pub 2023.
8. Rav E, Anjier A, Acharya S, Basar R, Wang Y, Daw NC, Rezvani K, Gopalakrishnan V, Gorlick R, Kleinerman E, Gordon N. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. Immunology 2023 Annual Conference, Washington, DC,, 2023. e-Pub 2023.
9. Bronk JK, Zhang M, McAleer MF, McGovern SL, Lassen-Ramshad Y, Safwat A, Daw NC, Rainusso N, Mahajan A, Grosshans DR, Paulino AC. Comprehensive radiotherapy for pediatric Ewing sarcoma: Outcomes of a prospective proton study. ASTRO 2022 Annual Meeting 114(3):E489, 2022. e-Pub 2022.
10. Truong DD, Lamhamedi-Cherradi SE, Maitituoheti M, Beird H, Wu CC, Krishnan S, Ingram DR, McCall D, Cuglievan B, Futreal PA, Titus M, Lazar A, Wang WL, Rai K, MacLeod AR, Ratan R, Livingston JA, Daw NC, Hayes-Jordan A, Ludwig JA. The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT. CTOS 2022 Annual Meeting, Vancouver, Canada,, 2022. e-Pub 2022.
11. Van der Perk MEM, Cost NG, Bos AME, Brannigan R, Chowdhury T, Davidoff AM, Daw NC, Dome JS, Ehrlich P, Graf N, Geller J, Kalapurakal J, Kieran K, Malek M, McAleer MF, Mullen E, Pater L, Polanco A, Romao R, Saltzman AF, Walz AL, Woods AD, van den Heuvel-Eibrink MM, Fernandez CV. White paper: Onco-fertility in pediatric patients with Wilms tumor. 54th Congress of the International Society of Pediatric Oncology, Barcelona, Spain,, 2022. e-Pub 2022.
12. Ross A, Miller A, Wang X, Lu Z, Cartwright C, Ringwald-Smith K, Tyler M, Daw NC, Navid F, Abdelhafeez H, Neel M, Bishop MW, Talbot L. Factors influencing risk for deep surgical wound complications in pediatric patients after limb salvage surgery for osteosarcoma. CTOS 2021 Virtual Annual Meeting,, 2021. e-Pub 2021.
13. Ludwig JA, Federman NC, Anderson PM, Macy ME, Riedel RF, Davis LE, Daw NC, Wulff JE, Kim A, Ratan R, Baskin-Bey E, Breitmeyer JB, Meyers P. TK216 for Ewing sarcoma- Interim phase 1/2 results. CTOS 2021 Virtual Annual Meeting,, 2021. e-Pub 2021.
14. Becktell K, Chen Y, Yasui Y, Phelan R, Chow EJ, Armstrong GT, Oeffinger KO, Daw NC, Weil B, Weldon C, Schwartz CL. Long-term follow-up of survivors of childhood osteosarcoma (OS): A report from the Childhood Cancer Survivor Study (CCSS). 53th Virtual Congress of the International Society of Pediatric Oncology, 2021. e-Pub 2021.
15. Vera Recio CC, Dodd-Eaton EB, Corredor J, Gutierrez A, Daw NC, Arun B, Wang W. Identification and characterization of de novo TP53 mutation carriers in families with Li-Fraumeni Syndrome: A single institution experience. ASCO 2021 Annual Virtual Meeting,, 2021. e-Pub 2021.
16. Ludwig JA, Federman NC, Anderson PM, Macy ME, Riedel RE, Davis LE, Daw NC, Wulff J, Kim A, Ratan R, Baskin-Bey ES, Toretsky JA, Breitmeyer JB, Meyers PA. TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results. ASCO 2021 Annual Virtual Meeting,, 2021. e-Pub 2021.
17. Drissi R, Bockhold CA, Wu J, Daw NC, Dome JS. Alternative lengthening of telomeres (ALT) is the predominant mechanism for telomere maintenance in human osteosarcoma. AACR 2021 Conference, 2021. e-Pub 2021.
18. Gill J, Conley AP, Somaiah N, Araujo DM, Ratan R, Posey K, Benjamin RS, Patel S, Daw NC, Harrison DJ, Gorlick R, Lin H, Wang WL, Amini B, Gordon N, Livingston JA. A phase 1/2 trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma: Results of phase 1. CTOS 2020 Annual Meeting, Vancouver, Canada, 2020. e-Pub 2020.
19. Ludwig JA, Federman NC, Anderson P, Macy ME, Riedel RF, Davis L, Daw NC, Muscal JA, Kim A, Ratan R, Ianopulos X, Breitmeyer JB, Hsu FJ, Meyers P. Phase 1/2 Study of TK216, a novel anti-ETS agent for Ewing sarcoma. ESMO 2020 Virtual Congress,, 2020. e-Pub 2020.
20. Somaiah N, Conley PA, Lin H, Amini B, Sharjeel S, Araujo D, Benjamin RS, Livingston JA, Patel S, Ratan R, Ravi V, Zarzour MA, Wang WL, Tate TJ, Roland CL, Simmons T, Daw NC, Futreal AH, Lazar A, Wistuba II, Hwu P. A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas. ASCO 2020 Virtual Annual Meeting, (#11509),, 2020. e-Pub 2020.
21. Gordon N, Kleinerman ES, Sheshadri A, Blanco DW, Yedururi S, Morani A, Gill JB, Harrison DJ, Herzog CE, Livingston JA, Benjamin RS, Gorlick R, Mireles ME, Kawedia J, Daw NC. Phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases. ASCO 2020 Virtual Annual Meeting, (#TPS3645),, 2020. e-Pub 2020.
22. Dao L, Foglesong J, Batth I, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw NC, Li S. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. CTOS 2019 Annual Meeting, Tokyo, Japan,, 2019. e-Pub 2019.
23. Meyers P, Ludwig JA, Federman NC, Daw NC, Macy ME, Riedel RF, Muscal JA, Ianopoulos X, Breitmeyer J, Toretsky J. A phase 1 dose escalation study of intravenous TK216 in patients with relapsed or refractory Ewing sarcoma. CTOS 2019 Annual Meeting, Tokyo, Japan,, 2019. e-Pub 2019.
24. Msaouel P, Slack-Tidwell R, Genovese G, Daw NC, Siefker-Radtke AO, Tannir NM. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. Journal of Clinical Oncology 37 (7S):TPS678, 2019. e-Pub 2019.
25. Msaouel P, Slack Tidwell R, Genovese G, Siefker-Radtke AO, Daw NC, Tannir NM. Phase II Trial of Ixazomib combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Kidney Malignancies. ASCO 2019 Annual Meeting, San Francisco, CA,, 2019. e-Pub 2019.
26. Batth I, Zaky W, Rood S, Daw NC, Gill JB, Huang W, Chen D, Albert A, Khatua S, Li S. Pilot study of circulating tumor cells in pediatric high grade brain tumors. SNO 2018 Annual Meeting, New Orleans, LA,, 2018. e-Pub 2018.
27. Livingston JA, Beird HC, Wu C, Cao S, Advani SM, Ingram D, Wang WL, Lazar AJ, Leung CH, Lin HY, Reuben A, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Gorlick RG, Lewis VO, Futreal A, Daw NC. Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity. ASCO 2018 Annual Meeting, Chicago, IL; J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
28. Wu CC, Beird H, Livingston JA, Cao S, Advani SM, Ingram D, Wang WL, Lazar AJ, Reuben A, Zheng Y, Roszik J, Wang W, Gorlick RG, Benjamin RS, Patel S, Daw NC, Futreal A, Lewis VO. Genome and transcriptome profiling of relapsed and metastatic osteosarcoma. ASCO 2018 Annual Meeting, Chicago, IL; J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
29. Geller JI, Cost NG, Chi YY, Perlman EJ, Kim Y, Cajaiba M, Mullen EA, Glick RD, Khanna G, Daw NC, Ehrlich PF, Fernandez CV, Dome J. A prospective study of pediatric renal cell carcinoma: A report from the Children’s Oncology Group study AREN0321. ASCO 2018 Annual Meeting, Chicago, IL; J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
30. Phadnis S, Huh W, Herzog CE, Daw NC, Harrison DJ, Ward EN, Piha-Paul S, Bhatt T, Mote EP, Gorlick R, Meric-Bernstam F, Schwartz CL, Subbiah V. Phase I study of Everolimus (MTOR Inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in children, adolescents and young adults with sarcoma and other advanced solid tumors. CTOS 2017 Annual Meeting, Maui, HI,. e-Pub 2017.
31. Bishop MW, Chemaitilly W, Mao S, Wu J, Santana VM, Navid F, Daw NC. Markers of gonadal function in pediatric patients with osteosarcoma receiving standard chemotherapy in combination with bevacizumab. CTOS 2017 Annual Meeting, Maui, HI;. e-Pub 2017.
32. Daw NC, Chi YY, Kim Y, Kalapurakal JA, Hoffere FA, Giller JI, Perlma EJ, Enrlich PF, Gow KW, Mullen EA, Warwick A, Grundy PE, Gratias E, Ward DA, Anderson JR, Paulino AC, Tochner Z, Venkatramani R, Fernandez CV, Dome JS. Effect of chemotherapy dosage on outcome of patients with stage II-IV diffuse anaplastic Wilms tumor: Results from The Children's Oncology Group AREN0321 study. 49th Congress of the International Society of Pediatric Oncology, Washington, DC,, 2017. e-Pub 2017.
33. Geller J, Chi YY, Kalapurakal JA, Daw NC, Kim Y, Kalapurakal JA, Hoffer FA, Perlman EJ, Ehrlich PF, Mullen EA, Warwick A, Paulino A, Tochner Z, Gow K, Grundy P, Gratias E, Ward D, Anderson JR, Fernandez C, Dome JS. Rhabdoid tumor: Results from The Children’s Oncology Group AREN0321 study. Congress of the International Society of Pediatric Oncology, Washington, DC, 2017. e-Pub 2017.
34. Livingston JA, Posey K, Subbiah V, Daw NC, Somaiah N, Ravi V, Patel S, Benjamin RS, Wang W, Lazar AJ, Broaddus R, Meric-Bernstam F, Shaw K, Roszik J, Conley AP. Analysis of osteosarcoma subtypes by clinical genomic testing identifies clinically actionable alterations. ASCO 2017 Annual Meeting, Chicago, IL; J Clin Oncol 35(Suppl), 2017. e-Pub 2017.
35. Federman N, Meyers PA, Daw NC, Toretsky J, Breitmeyer JB, Singh AS, Miller LL, Oltersdorf T, Jezior D, Jessen KA, Lannutti B, Ludwig JA. A phase I, first-in-human, dose escalation study of intravenous TK216 in patients with relapsed or refractory Ewing sarcoma. ASCO 2017 Annual Meeting, Chicago, IL; J Clin Oncol 35, 2017. e-Pub 2017.
36. Livingston JA, Tsai JW, Advani S, Lazar A, Conley AP, Daw NC, Wang WL. Expression of PRAME in osteosarcoma tumor specimens. CTOS 21st Annual Meeting, Lisbon, Portugal,, 2016. e-Pub 2016.
37. Subbiah V, Anderson PM, Kairemo K, Huh WW, Ravi V, Daw, NC, Somaiah N, Benjamin RS, Hong DS, Ravizzini G, Rohren E. Alpha particle Radium-223 dichloride (223RaCI2) in high risk osteosarcoma. ASCO 2016 Annual Meeting, Chicago, IL,, 2016. e-Pub 2016.
38. Subbiah V, Anderson P, Winston H, Ravi V, Daw NC, Somaiah N, Kappadath C, Ravizzini G, Ludwig J, Chawla S, Benjamin RS, Patel S, Schwartz C, Hong DS, Rohren E. Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma. ASCO 2023 Annual Meeting, Chicago, IL,, 2015. e-Pub 2015.
39. Moonat HR, W-L W, Hess KR, Lopez-Terrada, D, Schwartz CL, Moise M, Patel S, Benjamin RS, Lewis VO, Lazar A, Daw NC. Small cell osteosarcoma: Clinical and histopathologic review of 30 cases. CTOS 20th Annual Meeting, Salt Lake City, UT,, 2015. e-Pub 2015.
40. Bishop MW, Villarroel M, Billups CA, Navid F, Rivera C, Quintana JA, Gattuso JS, Advani SM, Hinds PS, Daw NC. Health related quality of life and outcomes of pediatric patients with non-metastatic osteosarcoma treated in countries of different resources. CTOS 20th Annual Meeting, Salt Lake City, UT,, 2015. e-Pub 2015.
41. Hurley C, McCarville B, Shulkin BL, Mao S, Wu J, Navid F, Daw NC, Pappo AS, Bishop MW. Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. ASCO 2015 Annual Meeting, Chicago, IL,, 2015. e-Pub 2015.
42. Subbiah V, Kawedia JD, Christensen AM, Hess KR, Patel K, Wood E, Bitar RD, Daw NC. Comparison of adult oncology phase 1 trials to pediatric oncology phase 1 trials in the era of targeted therapies. ASCO 2015 Annual Meeting, Chicago, IL,, 2015. e-Pub 2015.
43. Anghelescu DL, Steen BD, Wu H, Wu J, Daw NC, Hankins GM, Faughnan LG, Navid F. Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. 5th International Congress on Neuropathic Pain, Nice, France,, 2015. e-Pub 2015. PMID: 27573717.
44. Morani AC, Smith EA, Huh W, Daw NC, Hayes-Jordan A, Dillman JR. Benign and malignant masses of the pediatric peritoneal cavity (including mesentery and omentum). Society for Pediatric Research, Bellevue, WA,, 2015. e-Pub 2015.
45. Ramani NS, Morani A, Daw NC, Hughes D, Herzog C. Positive β- hCG in osteosarcoma: A myth or fact?. American Society of Pediatric Hematology/Oncology 27th Annual Meeting, Chicago, IL,, 2014. e-Pub 2014.
46. Mullen EA, Gooskens SLM, Hamilton TE, van den Heuvel-Eibrink MM, Green DM, Grundy PE, Daw NC, Dome JS, Fernandez CV. Sinusoidal obstruction syndrome during treatment for renal tumors in NWTS 3, 4 and 5: Incidence, severity and effect on planned treatment and outcome. 44th Congress of the International Society of Pediatric Oncology, London, UK, 59(6):1010-1011, 2012. e-Pub 2012.
47. Kaste SC, Brady SL, Yee BS, McPherson VL, Li Y, Daw NC, Kaufman RA, Pappo AS. Off-therapy CT monitoring of patients with Wilms tumor: Is pelvic CT necessary?. The International Society for Pediatric Radiology Meeting, London, UK,, 2011. e-Pub 2011.
48. Juergens H, Daw NC, Oberlin O, Ferrari S, Villarroel M, Doz F, Whelan JS, Wang T, Paccagnella L, Gualberto A. Efficacy and safety results from a Phase 1/2 study of the anti-IGF-IR antibody Figitumumab in patients with refractory Ewing sarcoma. European Society for Medical Oncology, 35th Congress, Milan, Italy, 2010. e-Pub 2010.
49. Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patino-Garcia A, Trpisi R, Hoover RN, Douglass C, Schuz J, Craft AW, Savage SA. Height, birth-weight, and osteosarcoma risk in a large meta-analysis. 101st AACR Annual Meeting, Washington, DC, (abstract # 5748), 2010. e-Pub 2010.
50. Al-Rahawan MM, Yang J, Wang C, Aldag JC, de Alarcon PA, West N, Hinds PS, Rubnitz JE, Daw NC. Anemia and health-related quality of life in pediatric patients undergoing treatment for acute myeloid leukemia or osteosarcoma. 23rd annual meeting of the American Society of Pediatric Hematology/Oncology, Montreal, Canada,, 2010. e-Pub 2010.
51. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins J, Villarroel M, Luchtman-Jones L, Quintana J, Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ASCO Annual Meeting, Orlando, FL; Cancer 117(12):2770-8, 2011 27:528s (abstract #10036), 2009. e-Pub 2009. PMID: 21656756.
52. Ros C, Sedlacik J, Daw NC, Loeffler R, Reichenbach JR, Hillenbrand CM. Boosting image quality by automatic low SNR channel detection and its removal in k-space. International Society for Magnetic Resonance in Medicine, 17th Scientific Meeting, Honolulu, HI 17, 2853 (abstract #5630), 2009. e-Pub 2009.
53. Hossain AM, Shulkin BL, Bashir H, Daw NC, Dome JS. FDG PET CT scans in patients with Wilms tumor. 55th Annual Meeting of the Society of Nuclear Medicine, New Orleans, LA,, 2008. e-Pub 2008.
54. Schaiquevich P, Panetta JC, Throm S, Daw NC, Geyer JR, Furman W, Stewart CF. Population pharmacokinetic (PK) analysis of getitinib in pediatric cancer patients. ASCO 2008 Annual Meeting, Chicago, IL, 26:117s (abstract #2523), 2008. e-Pub 2008.
55. Leary SE, Billups CA, Watkins A, Wu J, Poe D, Neel MN, Rao BN, Daw NC. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital Experience. ASCO Annual Meeting, Chicago, IL, 26:557s (abstract #10516), 2008. e-Pub 2008.
56. Reddick WE, Glass JO, Billups CA, Hoffer FA, Jenkins JJ, Quintana J, Villarroel M, Luchtman-Jones L, Daw NC. An international, multi-institutional trial of DCE-MRI in children treated for osteosarcoma. 16th Scientific Meeting of the International Society for Magnetic Resonance in Medicine, Toronto, Canada,, 2008. e-Pub 2008.
57. Reddick WE, Guo J, Ji Q, Glass JO, McCarville ME, Daw NC. Preliminary experience with 3D DCE-MRI evaluation of children treated for osteosarcoma with chemotherapy plus bevacizumab. International Society for Magnetic Resonance in Medicine, 17th Scientific Meeting, Honolulu, HI,, 2008. e-Pub 2008.
58. Reddick WE, Hoffer FA, Billups CA, Jenkins JJ, Wu J, Daw NC. Response assessment using dynamic MR imaging in non-metastatic osteosarcoma. ASCO Annual Meeting, Chicago, IL 25:549s (abstract #10018), 2007. e-Pub 2007.
59. Rivera GK, Quintana J, Villarroel M, Rodriguez C, Santana VM, Rideiro RC, Daw NC. Conduct of an international collaborative osteosarcoma trial at centers in a developed and developing country. ASCO 2007 Annual Meeting, Chicago, IL, 25:532s (abstract #9527), 2007. e-Pub 2007.
60. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale GA, Dalton JD, Billups CA, Dome JS, Daw NC, Khoury JD. EGFR expression and copy number gain are common in osteosarcoma. US and Canadian Academy of Pathology Annual Meeting, San Diego, CA,, 2007. e-Pub 2007.
61. Dome J, Freeman B, Billups C, Hoffer F, Wu J, Coppes M, Grant R, Chintagumpala M, Mullen E, Alvarado C, Daw NC, Stewart C, Metzger M. Anti-tumor activity of topotecan against Wilms tumor: Results of a multi-institutional phase II study. 38th Annual Conference of the International Society of Paediatric Oncology, Geneva, Switzerland, 47(4):453 (abstract #PD.094), 2006. e-Pub 2006.
62. Kaste SC, Waszilycsak G, McCarville MB, Daw NC. Excess cancer mortality in pediatric thallium imaging. 2006 Society of Pediatric Radiology and European Society of Paediatric Radiology's Fifth Conjoint Meeting, Montreal, Quebec, Canada, 2006. e-Pub 2006.
63. McCarville MB, Reddick WE, Xiong X, Kaste SC, Daw NC. Clinical significance of the 201 Thallium donut-sign in primary extremity osteosarcoma. 2006 Society of Pediatric Radiology and European Society of Paeditric Radiology's Fifth Conjoint Meeting, Montreal, Quebec, Canada,, 2006. e-Pub 2006.
64. Motl SE, Freeman BB III, Muralidharan BK, Panetta JC, Daw NC, Geyer JR, Furman WL, Stewart CF. Population pharmacokinetic analysis of gefitinib in pediatric cancer patients. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA,, 2005. e-Pub 2005.
65. Rodriguez-Galindo C, Navid F, Liu T, Billups C, Krasin M, Spunt SL, Daw NC, Rao B, Santana V. Prognostic factors and risk stratification in Ewing sarcoma family of tumors (ESFT). International Society of Paediatric Oncology XXXVII Meeting, Vancouver, Canada. Pediatric Blood Cancer, 45(4);402 (abstract #O.075), 2005. e-Pub 2005.
66. Hoffer F, Spunt S, Daw NC. Radiofrequency ablation of pediatric acquired metastases, a Phase I study. International Society of Paediatric Oncology XXXVII Meeting, Vancouver, Canada, Pediatric Blood Cancer, 45(4):444 (abstract #P.B.006), 2005. e-Pub 2005.
67. Iacono LC, Furman WL, Crews KR, Panetta JC, Freeman BB, Daw NC, Stewart CF. Effect of gefitinib on the systemic disposition of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors. ASCO 40th Annual Meeting 22, No 14S:129s (abstract #2011), 2004. e-Pub 2004.
68. Daw NC, Furman WL, Stewart CV, Iacono LC, Krailo M, Bernstein M, Dancey JE, Blaney S, Adamson PC. A phase I trial and pharmacokinetic study of gefitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. ASCO 40th Annual Meeting, New Orleans, LA, Proc Am Soc Clin Oncol, 22, No. 14S:804s (abstract #8521), 2004. e-Pub 2004.
69. Furman WL, Daw NC, Crews KR, Stewart CF, McCarville M, Santana VM, Hawkins D, Rodriguez-Galindo C, Navid F, Houghton PJ. A phase I study of gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors. ASCO 40th Annual Meeting No 14S:14S:804s (abstract #8521), 2004. e-Pub 2004.
70. McCarville MB, Romano E, Daw NC, Xiong X, Reddick W, Kaste S. Etiology of the 201 Thallium "donut sign" in primary osteogenic sarcoma. Society for Pediatric Radiology Annual Meeting, Savannah, GA, 34:S1-S95, 2004. e-Pub 2004.
71. Neel MD, Heck RH, Daw NC, Rao BN. The repiphysis noninvasive expandable prosthesis for reconstruction following tumor resection around the knee. 12th International Symposium on Limb Salvage, de Janeiro, Brazil,, 2003. e-Pub 2003.
72. Daw NC, Iacono LC, Santana VM, Furman WL, Hawkins DR, Houghton PJ, Stewart CF. Phase I and pharmacokinetic study of oral topotecan (TPT) administered once daily on a ten-day schedule to pediatric patients with solid tumors. ASCO Annual Meeting, Chicago, IL, Proc Am Soc Clin Oncol, 22:810(abstract #3254), 2003. e-Pub 2003.
73. Daw NC, Rodriguez-Galindo C, Billups CA, Rao BN, Pratt CB, Meyer WH. Metastatic osteosarcoma: Results of two consecutive therapeutic trials at St. Jude Children's Research Hospital. ASCO Annual Meeting, Orlando, FL, Program/Proc Am Soc Clin Oncol 21(392a Abstract #1566), 2003. e-Pub 2003.
74. Sajadi KR, Heck RN, Neel MD, Rao BN, Daw NC, Rodriguez-Galindo C, Hoffer FA, Stacy GS, Peabody TD, Simon MA. The incidence and prognosis of osteosarcoma skip metastases. 26th Annual Meeting of the Musculoskeletal Tumor Society, Chicago, IL,, 2003. e-Pub 2003.
75. Furman WL, Crews K, Daw NC, Rodriguez-Galindo C, Stewart C, Houghton PJ, Santana VM. Cefixime (CFX) enables further dose-escalation of oral irinotecan (IRN) in pediatric patients with refractory solid tumors. ASCO Annual Meeting, Chicago, IL; Proc Am Soc Clin Oncol, 22:798(abstract #3206), 2003. e-Pub 2003.
76. Wodowski KS, Andreansky M, Rao BN, Pratt CB, Daw NC. Osteosarcoma in children aged 5 years and younger. Pediatric Academic Societies' Meeting, Baltimore, MD; J Pediatr Hematol Oncol, 23(3):A17(abstract #1432), 2002. e-Pub 2002.
77. Neel MD, Daw NC, Rodriguez-Galindo C, McCarville B, Rao B. Survival after local recurrence of osteosarcoma (OS): The St. Jude Children's Research Hospital experience, 1970-2000. 25th Annual Meeting of the Musculoskeletal Tumor Society, Toronto, Canada,, 2002. e-Pub 2002.
78. Crews KR, Stewart CF, Rodriguez-Galindo C, Pratt CB, Liu T, Daw NC. Effect of ifosfamide on the pharmacokinetics of irinotecan in patients with osteosarcoma. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA,, 2002. e-Pub 2002.
79. Neel MD, Toy PC, Britton L, Daw NC, Rodriguez-Galindo C, Billups CA, Rao BN. 20 Year experience with the Lacey Rotating Hinge (LRH) - Implant survival and mechanisms of failure in children. International Symposium for Limb Salvage Surgery, Birmingham, England,, 2001. e-Pub 2001.
80. Neel M, Toy P, Daw NC, Rodriguez-Galindo C, Kaste S, Pratt C, Rao B. Endoprosthetic survival following reconstruction in the skeletally immature patient (SIP). International Society of Paediatric Surgical Oncology XXXIII Meeting, Brisbane, Australia, October 2001. Med Pediatr Oncol 37(3):342 (Abstract #IO22), 2001. e-Pub 2001.
81. Neel MD, Rodriguez-Galindo C, Pratt CB, Daw NC, Pappo AS, Kaste SC, Rao BN. Limb salvage surgery about the knee in children under age 10. International Society of Paediatric Surgical Oncology Annual Meeting, Orlando, FL,, 2000. e-Pub 2000.
82. Daw NC, Pappo AS, Mahmoud HH, Rodriguez-Galindo C, Merchant TE, Jenkins JJ, Pratt CB, Rao BN. Malignant fibrous histiocytoma of soft tissue in children: a review of 26 cases. International Society of Pediatric Surgical Oncology Annual Meeting, Orlando, FL,, 2000. e-Pub 2000.
83. Daw NC, Rodriguez-Galindo C, Rao B, Kaste S, Jenkins J, Pratt C. Outcome of patients presenting with a single pulmonary metastasis more than one year after diagnosis of osteosarcoma. ASCO Annual Meeting, New Orleans, LA. Proceedings of the American Society of Clinical Oncology 19(Abstract #2345):596a, 2000. e-Pub 2000.
84. Daw NC. Bone tumors of childhood and adolescence. National Arab American Medical Association 16th International Medical Convention, Damascus, Syria,, 1999. e-Pub 1999.
85. Daw NC, Jones D, Gregornik D, Wilimas J, Marina N, Shearer P, Jenkins J, Shah A, Tan M, Rodman J. Renal function after ifosfamide, carboplatin and etoposide (ICE), nephrectomy, and radiation in children with high-risk Wilms tumor. ASCO Annual Meeting, Atlanta, GA. Proceed American Society of Clinical Oncology 15(Abstract #2159):560a, 1999. e-Pub 1999.
86. Daw NC, Pappo AS, Rao BN, Merchant TE, Jenkins JJ, Pratt CB. Pediatric leiomyosarcoma: the St. Jude Children's Research Hospital experience. Med Pediatr Oncol 33(3):291 (Abstract #76), 1999. e-Pub 1999.
87. Daw NC, Mahmoud HH, Meyer WH, Pratt CB, Rao BN. Bone sarcomas of the head and neck in children: St. Jude Children's Research Hospital experience. International Society of Pediatric Oncology XXVIIIth Meeting, Vienna, Austria. Med Pediatr Oncol 27(Abstract #O-59):226, 1996. e-Pub 1996.
88. Daw NC, Mohmoud HH, Meyer WH, Pratt CB, Rao BN. Bone sarcomas of the head and neck in children: The St. Jude Children's Research Hospital (SJCRH) experience. ASCO Annual Meeting, Philadelphia, PA, 15(Abstract #1454):463, 1996. e-Pub 1996.
89. Daw NC, Wilimas J, Wang W, Presbury G, Joyner R, Harris S, Davis Y, Chen G, Chesney PJ. Nasopharyngeal carriage of resistant streptococcus pneumoniae in children with sickle cell disease: prevalence, risk factors and implications. 21st Meeting of the National Sickle Cell Program Abstract #058, 1996. e-Pub 1996.
90. Daw NC, Wilimas JA, Wang WC, Prebury GJ, Joyner RE, Harris SC, Davis Y, Chesney PJ. Nasopharyngeal carriage of resistant streptococcus pneumoniae (SP) in children with sickle cell disease (SCD). American Society for Pediatric Research Annual Meeting 37:157A, 1995. e-Pub 1995.
91. Daw NC, Arnold JT, White MM, Stenberg PE, Jackson CW. Regulation of thrombopoiesis: in vivo response to a single injection of murine peg-megakaryocyte growth and development factor. Blood 86(Suppl 1):897a, 1995. e-Pub 1995.
92. Poche AL, Song J, Koutroumpakis E, Roth ME, Livingston JA, Daw NC, Hildebrandt MAT, Deswal A, Kleinerman ES, Chandra J. Longitudinal redox imbalance and early cardiac dysfunction in anthracycline-treated AYA sarcoma survivors. Cancer Survivorship Research Retreat, Houston, TX,.
93. Armstrong AE, Daw NC, Renfro L, Geller JI, Kalapurakal JA, Khanna G, Paulino AC, Perlman EJ, Ehrlich PF, Gow KW, Warwick AB, Grundy PE, Fernandez CV, Mullen EA, Dome JS. Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies. ASCO 2023 Annual Meeting, Chicago, IL,.
94. Truong DD, Arslan E, Kochat V, Krishnan S, Agyemang C, Divenko M, Ingram D, Lascano Segura R, Basi A, Gomez J, Beird H, Wu CC, Burks J, Futreal A, Lazar A, Ratan R, Daw NC, Hayes-Dixon A, Rai R, Ludwig JA. Multi-omic analysis of desmoplastic small round cell tumors reveal distinct lineages. CTOS 2023 Annual Meeting, Dublin, Ireland,.
95. Nash A, Ratan R, Somaiah N, Conley AP, Lewis VO, Wang WL, Lin HY, Daw NC, Gill JB, Harrison DJ, Gorlick RG, Patel S, Livingston JA. Harmonizing cancer care delivery for AYAs with osteosarcoma: Comparison of pediatrics and adult approaches in a single center. ASCO 2024 Annual Meeting, Chicago, IL,.
96. Livingston A, Gill J, Conley A, Somaiah N, Araujo D, Ratan R, Ravi V, Zarzour A, Benjamin R, Patel S, Daw NC, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. A phase 1/2 trial of gemcitabine/docetaxel and hydroxychloroquine in advanced metastatic osteosarcoma. 2024 ESMO Congress, Barcelona, Spain,.
97. Livingston A, Gill J, Conley A, Somaiah N, Araujo D, Ratan R, Ravi V, Zarzour A, Benjamin R, Patel S, Daw NC, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. A phase 1/2 trial of gemcitabine/docetaxel and hydroxychloroquine in advanced metastatic osteosarcoma. CTOS 2024 Annual Meeting, San Diego, CA,.
98. Esbenshade AJ, Kutny M, Dunkel IJ, Dome JS, Luna-Fineman S, Nunez C, Slone J, Frazier AL, O’Neill AF, Geller J, Lupo P, Peterson R, Chintagumpala M, Embry L, Daw NC, Xavier AC, Libes JM, Saab R. Global health partnership and research interest among North American pediatric oncology health care professionals: A report from SIOP North America (SIOP NA). 56th Congress of International Society of Paediatric Oncology, Honolulu, HI,.
99. Truong DD, Arslan E, Kochat V, Krishnan S, Agyemang C, Divenko M, Cardenas R, Ingram D, Lazcano R, Basi A, Gomez J, Beird HC, Wu C, Burks J, Futreal P, Lazar A, Ratan R, Daw NC, Hayes-Dixon A, Rai K, Ludwig AJ. Exploring the heterogeneity of desmoplastic small round cell tumors through multi-omics analyses uncovers epithelial and neuroendocrine lineages. CTOS 2024 Annual Meeting, San Diego, CA,.
100. Truong DD, Arslan E, Kochat V, Fan J, Shamsutdinova D, Ingram D, Agyemang C, Cardenas R, Ahmed A, Magrath J, Beird HC, Futreal PA, Lazar A, Ratan R, Daw NC, Lee SB, Hayes-Dixon A, Bai K, Ludwig J. EWSR1:WT1 Fusion oncoprotein activity shapes lineage heterogeneity in desmoplastic small round cell tumors. CTOS 2025 Annual Meeting, Boca Raton, FL,.
101. Nakazawa MS, Yalamanchili S, Bishop A, Conley AP, Zarzour MA, Araujo DM, Nassif Haddad EF, Ratan R, Benjamin R, Patel S, Somaiah N, Gorlick R, Daw NC, Goepfert R, Wang W, Guadagnolo BA, Livingston JA. Outcomes of multimodal perioperative treatment in osteosarcomas of the jaw. CTOS 2025 Annual Meeting, Boca Raton, FL,.
102. Viguet C, Hughes A, Banchs J, Gilchrist SC, Rauschendorfer S, Jayabal P, Song J, Honey TA, Chandra J, Daw NC, Hildebrandt MAT, Livingston JA, Ali HR, Roth M, Kleinerman ES, Deswal A, Kapadia T, Koutroumpakis E. Longitudinal echocardiographic assessment of subacute cardiotoxicity in a prospective cohort of adolescents and young adults with sarcoma treated with high-dose doxorubicin. 2025 American Heart Association Scientific Sessions, New Orleans, LA,.
103. Ludwig JA, Federman N, Anderson P, Macy M, Davis LA, Riedel RF, Daw NC, Muscal J, Ratan R, Toretsky J, Ianopulos X, Hsu F, Breitmeyer J, Meyers P. TK216 Phase 1 study in metastatic, relapsed/refractory Ewing sarcoma. CTOS 2020 Virtual Meeting.
104. Truong D, Lamhamedi-Cherradi SE, Maitituoheti M, Beird HC, Arslan E, Wu CC, Krishnan S, Ingram D, Futreal PA, Titus M, Rai K, Lazar K, Macleod AR, Ratan R, Livingston JA, Daw NC, Hayes-Dixon A, Ludwig J. The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT. CTOS 2022 Annual Meeting 83(7).
105. Daw NC, Chi YY, Mullen EA, Kalapurakal JA, Tian J, Khanna G, Geller JI, Perlman EJ, Ehrlich PF, Warwick A, Fernandez CV, Grundy PE, Dome JS. Treatment of stage I focal or diffuse anaplastic Wilms tumor: A report from the Children’s Oncology Group. 48th Congress of the International Society of Pediatric Oncology, Dublin, Ireland,.
106. Bishop MW, Villarroel M, Fuenzalida M, Quintana JA, Mao S, Wu J, McPherson V, Jenkins JJ, Rao BN, Neel MD, Santana VM, Navid F, Daw NC. Ten-year survival of patients with localized osteosarcoma treated without methotrexate. CTOS 21st Annual Meeting, Lisbon, Portugal,.
107. Beird HC, Wu CC, Livingston JA, Advani S, Ingram D, Wang WL, Leung H, Lin H, Reuben A, Cao S, Zheng Y, Roszik J, Wang W, Lazar A, Futreal A, Lewis V, Gorlick R, Daw NC. SOX2/OCT4-High subgroup of osteosarcoma has high PD-L1. CTOS 2018 Annual Meeting, Rome, Italy,.
108. Tarek N, Kim SU, Souki TS, Daw NC. Primary Ewing sarcoma/ primitive neuroectodermal tumor of the kidney: A single institution experience. American Society of Pediatric Hematology/Oncology 27th Annual Meeting, Chicago, IL,.
109. Egas-Bejar DE, Slopis J, Ceja ME, Corrales-Medina FF, Herzog C, Daw NC. Ifosfamide-induced encephalopathy in children and young adults: The MD Anderson Cancer Center experience. American Society of Pediatric Hematology/Oncology 27th Annual Meeting, Chicago, IL,.
110. Gordon N, Daw NC, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Aerosol interleukin-2 for the treatment of patients ≥12 years old with osteosarcoma lung metastases: A phase I trial. American Society of Pediatric Hematology/Oncology 27th Annual Meeting, Chicago, IL,.
111. Daw NC, Anderson JR, Hoffer FA, Geller JI, Kalapurakal JA, Perlman EJ, Ehrlich PF, Mullen EA, Gratias E, Grundy PE, Dome JS. A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children’s Oncology Group AREN0321 study. ASCO 2014 Annual Meeting, Chicago, IL,.
112. Pan H, Morani A, Wang W, Hess KR, Lin PP, Daw NC, Mahajan A. Utility of histologic and radiologic response to induction chemotherapy in patients with Ewing sarcoma (EWS). ASTRO 56th Annual Meeting, San Francisco, CA,.
113. Loh AH, Wu H, Bahrami A, Navid F, Bishop M, McCarville MB, Wu J, Daw NC, Neel MD, Rao BN. Reducing longitudinal bony resection margins in limb-sparing surgery for extremity osteosarcoma does not impact oncologic outcomes. 46th Congress of the International Society of Paediatric Oncology, Toronto, Canada,.
114. Navid F, Santana VM, McCarville MB, Shulin BL, Neel M, Mao S, Wu J, Billups CA, Jenkins JJ, Pappo AS, Willert JR, Loeb DM, Ahn H, Rao BN, Daw NC. A Phase II Trial evaluating the feasibility of adding bevacizumab to the therapy for localized osteosarcoma. CTOS 19th Annual Meeting, Berlin, Germany,.
115. Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog C, Hughes D, Monge OR, Alvaro L, Rubino J, Pathiraja K, Yao SL, Lu B, Ayers M, Mauro D. Clinical activity of Robatumumab in patients with relapsed osteosarcoma and Ewing sarcoma. CTOS 19th Annual Meeting, Berlin, Germany,.
116. Daw NC, Anderson JR, Kalapurakal JA, Hoffer FA, Geller JI, Perlman EJ, Ehrlich PF, Mullen EA, Warwick A, Grundy PE, Dome JS. Treatment of stage II-IV diffuse anaplastic Wilms tumor: Results from the Children's Oncology Group AREN0321 study. 46th Congress of the International Society of Paediatric Oncology, Toronto, Canada,.
117. Gordon N, Daw NC, Anderson P, Guma S, Chien HC, Zinner R, Subbiah V, Hajjar J, Kleinerman ES, Naing A. Aerosol Interleukin-2 for the treatment of patients ≥12 years old with lung metastases from osteosarcoma: A phase I trial. Society for Immunotherapy of Cancer 29th Annual Meeting, National Harbor, MD,.
118. Salem UI, Amini B, Chuang HH, Daw NC, Wei W, Costelloe CM, Haygood TM, Madewell JE. 18F-FDG PET/CT as an indicator of survival in bone primary Ewing sarcoma. RSNA 100th Scientific Assembly and Annual Meeting, Chicago, IL,.
119. Salem UI, Amini B, Chuang HH, Daw NC, Wei W, Costelloe CM, Haygood TM, Madewell JE. 18F-FDG PET/CT as an indicator of survival in bone primary Ewing sarcoma. Society of Skeletal Radiology 38th Annual Meeting, Scottsdale, AZ,.
120. Subbiah V, Roxas M, Huh W, Khatua S, Herzog CE, Daw NC, Zaky W, Rytting M, Hughes DP, Daneshmand M, Berry J, Mote E, Ward E, Meric-Bernstam F, Kleinerman E, Schwartz C. Phase 1 evaluation of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) or Vemurafenib (BRAF inhibitor) in children and adolescents with advanced cancers. American Society of Pediatric Hematology/Oncology 28th Annual Meeting,.
121. Muscal JA, Orth RC, Ahern CH, Wagner LM, DuBois SG, O'Neill AF, Grant FD, McCowage GB, London K, Weigel BJ, Daw NC, Hawkins DS, Bagatell R. Comparison of FDG-PET and conventional imaging at diagnosis in pediatric patients with rhabdomyosarcoma. 17th CTOS Annual Meeting, Prague, Czech Republic,.
122. Huh WW, Daw NC, Herzog CE, Hughes DPM, Munsell MF, McAleer MF, Lewis VO. Ewing sarcoma family of tumors (ESFT) in children younger than 10 years of age: The MD Anderson Cancer Center experience. 17th CTOS Annual Meeting, Prague, Czech Republic,.
123. Huh WW, Chou AJ, Jaffe N, Rao BN, Billups C, Rodriguez-Galindo C, Meyers PA, Daw NC. Outcome of patients with a single pulmonary metastasis more than one year after diagnosis of osteosarcoma. 17th CTOS Annual Meeting, Prague, Czech Republic,.
124. Huh WW, W-L W, Lazar A, Daw NC, Herzog CE, Hughes DPM, Anderson PM, Munsell MF, McAleer MF, Hayes-Jordan A. Undifferentiated soft-tissue sarcoma in children and young adults: The MD Anderson Cancer Center Experience. 17th CTOS Annual Meeting, Prague, Czech Republic,.
125. Bohl C, McCarville B, Daw NC, Sandlund J, Navid F, Santana V, Federico SM, Shulkin BL. FDG PET CT for the evaluation of primary & secondary pancreatic malignancies in children. SNMMI Annual Meeting, Vancouver, Canada,.
126. Shulkin BL, Davis JC, Navid F, Billups C, Santana V, Gene R, Daw NC. FDG PET/CT in pediatric osteosarcoma: Comparison of standard & delayed scanning. SNMMI Annual Meeting, Vancouver, Canada,.
127. Egas-Béjar D, Hayes-Jordan A, Stewart J, Daw NC, Huff V, Corrales-Medina F, Huh W. Extrarenal Wilms tumor presenting as an abdominal wall mass. Children's Oncology Group Meeting, Dallas, TX,.
128. Yedururi S, Gladish G, Anderson P, Hughes D, Morani A, Daw NC. Cardiovascular metastases of osteosarcoma: Spectrum of imaging findings and analysis of 19 patients. RSNA 99th Scientific Assembly and Annual Meeting.
129. Gordon NB, Daw NC, Anderson P, Guma S, Chien HC, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Aerosol interleukin-2 for the treatment of patients ≥ 12 years old with osteosarcoma lung disease: A phase I/II study. AACR Annual Meeting, San Diego, CA,.
130. Satelli A, Daw NC, Lee ZB, Xia X, Ludwig J, Torres KE, Somaiah N, Gordon N, Zweidler-McKay PA, Tomaras M, Herzog CE, Griffin MA, Ingram L, Hughes D, Foglesong JS, Huh W, Kleinerman ES, Li S. Universal marker for circulating tumor cell detection from pediatric-type of tumors. American Society of Pediatric Hematology/Oncology 27th Annual Meeting, Chicago, IL,.
131. McCarville MB, Spunt SL, Daw NC, Kaste SC. The utility of PET-CT in the evaluation of childhood sarcomas. Society for Pediatric Radiology Annual Meeting, Savannah, GA,.
132. Daw NC, Kirstein MN, Santana VM, Furman WL, Houghton PJ, Stewart CF. Toxicity and pharmacokinetics of oral topotecan (TPT) in children with recurrent solid tumors. ASCO Annual Meeting, San Francisco, CA; Proc Am Soc Clin Oncol, 20:371a (Abstract #1499).
133. Rodriguez-Galindo C, Crews KR, Charlebois N, Stewart CF, Santana VM, Furman WL, Daw NC, Houghton PJ. Phase I study of the combination of topotecan (T) and irinotecan (I) in children with refractory solid tumors. ASCO Annual Meeting, San Francisco, CA; Proc Am Soc Clin Oncol, 20:378a (Abstract #1506).
134. Drews KR, Liu T, Rodriguez-Galindo C, Pratt CB, Tan M, Panetta JC, Meyer WH, Link MP, Daw NC. High-dose methotrexate (HDMTX) pharmacokinetics in osteosarcoma. ASCO Annual Meeting, San Francisco, CA; Proc Am Soc Clin Oncol 20:371a (Abstract #1480).
135. Daw NC, Rodriguez-Galindo C, Fortenberry T, McCarville B, Billups CA, Pratt CB, Rao BN. Osteosarcoma of the pelvis: The St. Jude Children's Research Hospital Experience. International Society of Paediatric Oncology XXXIII Meeting, Brisbane, Australia,. Med Pediatr Oncol, 17(3):212 (Abstract #P13).
136. Abushallaih B, Pestina TI, Daw NC, Jackson CW. An initial dose of pegylated recombinant mouse Megakaryocyte Growth and Development Factor (MGDF) primes the thrombopoietic system to be more responsive to subsequent MGDF administration. Application to a lethal myelosuppressive model. Seventh Midwest Platelet Conference, Memphis, TN,.
137. Arnold JT, Daw NC, Stenberg PE, Jackson CW. Increased platelet production in response to pegylated murine megakaryocyte growth and development factor (MGDF) results from in vivo stimulation of megakaryocyte proliferation and maturation. Keystone Symposia Conference on Molecular Regulation of Platelet Production, Taos, NM,.

Book Chapters

1. Daw NC, Ragoonanan D. Neoplasms of the Kidney: Wilms Tumor. In: Nelson Textbook of Pediatrics. Elsevier, 3130-3135.e1, 2024.
2. Daw NC, Ragoonanan D. Neoplasms of the Kidney: Other Pediatric Renal Tumors. In: Nelson Textbook of Pediatrics. Elsevier, 3135.e1, 2024.
3. Gordon N, Felix K, Daw NC. Aerosolized Chemotherapy for Osteosarcoma. In: Advances in Experimental Medicine and Biology. Springer International Publishing, 67-73, 2020.
4. Daw NC, Nehme G, Huff V. Neoplasms of the Kidney. In: Nelson Textbook of Pediatrics. 21. Elsevier, Inc, 2681-2685, 2019.
5. Bitar RD, Daw NC. Renal Cell Carcinoma in Children. In: Rare Kidney Tumors. Springer International Publishing, 31-42, 2018.
6. Daw NC, Huff V, Anderson PM. Neoplasms of the Kidney. In: Nelson Textbook of Pediatrics 21st ed. 20. Elsevier Saunders, 2464-2468, 2013.

Letters to the Editor

1. Dome JS, Mullen EA, Dix DB, Gratias EJ, Ehrlich PF, Daw NC, Geller JI, Chintagumpala M, Khanna G, Kalapurakal JA, Renfro LA, Perlman EJ, Grundy PE, Fernandez CV. Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. Letter to the Editor. J Natl Compr Canc Netw 20: XLVII-XLVIII, 2022.
2. McCarville MB, Lederman H, Santana VM, Daw NC, Shochat SJ, C-S L, Kaufman RA. Distinguishing benign from malignant pulmonary nodules with helical chest CT in children with malignant solid tumors. Letter to the Editor. Radiology, http://radiology.rsnajnls.org/cgi/eletters/239/2/514, 2008.